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OBJECTIVE—Several single nucleotide polymorphisms (SNPs)
in diabetes risk genes reduce glucose- and/or incretin-induced
insulin secretion. Here, we investigated interactions between
glycemia and such diabetes risk polymorphisms.
RESEARCH DESIGN AND METHODS—Insulin secretion was
assessed by insulinogenic index and areas under the curve of
C-peptide/glucose in 1,576 subjects using an oral glucose toler-
ance test (OGTT). Participants were genotyped for 10 diabetes
risk SNPs associated with -cell dysfunction: rs5215 (KCNJ11),
rs13266634 (SLC30A8), rs7754840 (CDKAL1), rs10811661
(CDKN2A/2B), rs10830963 (MTNR1B), rs7903146 (TCF7L2),
rs10010131 (WFS1), rs7923837 (HHEX), rs151290 (KCNQ1), and
rs4402960 (IGF2BP2).
Furthermore, the impact of the interaction between genetic
variation in TCF7L2 and glycemia on changes in insulin secretion
was tested in 315 individuals taking part in a lifestyle intervention
study.
RESULTS—For the SNPs in TCF7L2 and WFS1, we found a
signiﬁcant interaction between glucose control and insulin secre-
tion (all P  0.0018 for glucose  genotype). When plotting
insulin secretion against glucose at 120 min OGTT, the compro-
mising SNP effects on insulin secretion are most apparent under
high glucose. In the longitudinal study, rs7903146 in TCF7L2
showed a signiﬁcant interaction with baseline glucose tolerance
upon change in insulin secretion (P  0.0027). Increased glucose
levels at baseline predicted an increase in insulin secretion upon
improvement of glycemia by lifestyle intervention only in carriers
of the risk alleles.
CONCLUSIONS—For the diabetes risk genes TCF7L2 and
WFS1, which are associated with impaired incretin signaling, the
level of glycemia determines SNP effects on insulin secretion.
This indicates the increasing relevance of these SNPs during the
progression of prediabetes stages toward clinically overt type 2
diabetes. Diabetes 59:3247–3252, 2010
T
ype 2 diabetes is a disorder characterized by
chronically elevated blood glucose levels due to
insulin resistance and a relative lack of compen-
satory pancreatic insulin secretion. Environmen-
tal triggers such as a sedentary lifestyle, physical
inactivity, and increased body weight play an important
role in the development of the disease. In this regard,
genetics and especially gene-environment interactions
play an important role. Recent research revealed more
than 25 gene variants leading to a higher risk for the
development of type 2 diabetes (1). Interestingly, most of
the diabetes risk genes alter -cell function (1). This
supports the hypothesis that the main genetic effect in the
development of type 2 diabetes could be impaired insulin
secretion. Neither environmental triggers nor genetics
alone can explain the multifactorial disease type 2 diabe-
tes, thus a close interaction between both is presumed
(2–4). Hence, environmental inﬂuences may determine an
individual’s susceptibility for single nucleotide polymor-
phism (SNP) effects, or vice versa genotype may designate
a person’s susceptibility toward environmental factors.
One “environmental” factor that plays a role early in the
pathogenesis of type 2 diabetes is elevated glucose. It is
well known that years before type 2 diabetes occurs,
glucose control is altered, as reﬂected by higher fasting
glucose and/or higher postprandial glucose (5). High glu-
cose exerts unfavorable effects on insulin sensitivity and
secretion, known as glucotoxicity (6,7). On the other hand,
elevated glucose levels are needed for the incretin effect.
Glucagon-like peptide 1–induced insulin secretion be-
comes fully active only in the hyperglycemic range (8,9).
Incretin-dependent insulin secretion might therefore be of
particular importance when compensatory insulin hyper-
secretion is required.
The aim of this study was to investigate whether glyce-
mia inﬂuences the effects of genetic variation associated
with type 2 diabetes on insulin secretion. We therefore
studied 10 genome-wide association study–derived vari-
ants that were furthermore found to inﬂuence -cell
function in subsequent studies (rev. in 1,10). Of these, 2 (in
the TCF7L2 and WFS1 loci) are associated with incretin-
stimulated insulin secretion (1). As the magnitude of
incretin-stimulated insulin secretion is dependent on ele-
vated glucose levels (8,9), we hypothesized that glucose
levels speciﬁcally interact with the effect of those SNPs on
insulin secretion both in cross-sectional and longitudinal
intervention studies.
RESEARCH DESIGN AND METHODS
The participants were selected from the ongoing Tu ¨bingen Family Study for
type 2 diabetes (11). In short, the aim of this study is to investigate individuals
at high risk but yet without known type 2 diabetes. We selected 1,576 subjects
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were available. According to the World Health Organization diagnostic
criteria, 1,079 subjects were identiﬁed as normal glucose tolerant (NGT), 143
showed impaired fasting glucose (IFG), 138 had impaired glucose tolerance
(IGT), and 112 had both IFG and IGT. In 82 subjects, type 2 diabetes was
newly diagnosed. Individuals on medication affecting glucose metabolism
were excluded. An additional 22 subjects were excluded because of implau-
sible insulin and/or glucose values.
The clinical characteristics of the study population are shown in supplemen-
tary Table 1 in the online appendix available at http://diabetes.diabetesjournals.
org/cgi/content/full/db10-0674/DC1. Informed written consent was obtained from
all participants, and the local ethics committee approved the protocol.
We also analyzed longitudinal data from a subgroup of 342 individuals who
were metabolically reanalyzed after a follow-up period of 9 months, during
which they took part in a lifestyle intervention program (see the online
appendix for additional information).
Selection of loci/SNPs. We selected representative SNPs in type 2 diabetes
risk loci previously reported to affect distinct aspects of -cell function:
KCNJ11 (rs5215), SLC30A8 (rs13266634), CDKAL1 (rs7754840), CDKN2A/2B
(rs10811661), MTNR1B (rs10830963), TCF7L2 (rs7903146), WFS1
(rs10010131), HHEX (rs7923837), KCNQ1 (rs151290), and IGF2BP2
(rs4402960). All SNPs were genotyped in the whole cohort in the course of
earlier studies (12–18) using TaqMan assays (Applied Biosystems, Foster City,
CA) and passed the quality controls. Details on this as well as on minor allele
frequencies, genotyping success rates, and Hardy-Weinberg equilibrium are
reported in the aforementioned references.
OGTT. After an overnight fast, subjects ingested a standard solution contain-
ing 75 g of glucose at 08:00 h. Plasma glucose, insulin, and C-peptide
concentrations were determined in venous blood samples obtained at 0, 30,
60, 90, and 120 min.
Plasma insulin and C-peptide were determined by commercial chemilumi-
nescence assays for ADVIA Centaur (Siemens Medical Solutions, Fernwald,
Germany). Blood glucose was measured using a bedside glucose analyzer
(glucose oxidase method; Yellow Springs Instruments, Yellow Springs, OH).
Calculations. Insulinogenic index (IGI) was calculated from the OGTT
([insulin30  insulin0]/[glucose30  glucose0]). Areas under the curve (AUCs)
were calculated according to the trapezoid method as: 0.5  (c0/2  c30 
c60  c90 c120/2) where c is concentration. OGTT-derived insulin sensitivity
index was estimated as described earlier (10).
Statistical analyses. Unless otherwise stated, data are given as means  SD.
Data that were not normally distributed were logarithmically transformed
prior to statistical analysis. To identify covariates interacting with SNP effects
on insulin secretion, we used ANCOVA. P values  0.05 were considered to
indicate nominal associations, after correction for multiple comparisons
taking into account the 10 genes tested (according to Bonferroni correction).
P values  0.0051 were considered statistically signiﬁcant. Differences be-
tween genotype groups were tested using multivariate linear regression
analysis. P values were determined using the additive and the dominant
inheritance models. After correction for multiple comparisons taking into
account the 2 genes tested further (according to Bonferroni correction), P
values  0.025 were considered statistically signiﬁcant. For statistical analy-
sis, JMP 7.0 (SAS Institute, Cary, NC) statistical software package was used.
RESULTS
We screened for the interaction of 120 min postload
glucose (glucose120), AUC of glucose, and A1C with effects
of the 10 SNPs on the insulin secretion parameters
AUCC-peptide/AUCGlucose and IGI by ANCOVA. After correc-
tion for multiple comparisons, TCF7L2 SNP rs7903146 and
WFS1 SNP rs10010131 showed signiﬁcant interaction with
AUCGlucose and glucose120 concerning their effect on insu-
lin secretion measured by C-peptide– or insulin-derived
secretion indexes. In addition, both variants showed nom-
inal interaction with A1C (Table 1). For the other 8 SNPs,
only a few interactions with secretion parameters were
detected (Table 1), which did not pass correction for
multiple comparisons.
The two SNPs that were affected by glucose control
were investigated in detail. Therefore, we stratiﬁed the
cohort for genotypes and plotted insulin secretion values
against glucose120 as a proxy for glycemia. Insulin secre-
tion was adjusted for possible confounders (sex, age, BMI,
and insulin sensitivity) by multivariate linear regression
analysis. Regression lines of these analyses are shown in
Fig. 1. The compromising effect of the risk alleles on
insulin secretion is most apparent under high glucose
conditions for the TCF7L2 SNP rs7903146 as well as for
the WFS1 SNP rs10010131. By contrast, when glucose
levels are low, no SNP effect on insulin secretion is
obvious or the risk allele may even be beneﬁcial. In this
respect, the T-allele of TCF7L2 SNP rs7903146 appears to
affect insulin secretion in a recessive way, whereas the
mode of action of the G-allele of WFS1 SNP rs10010131 is
less clear. Performing similar analyses for the other eight
SNPs resulted in no signiﬁcant interactions (supplemen-
tary Fig. 2).
To further evaluate the interaction of TCF7L2 rs7903146
and WFS1 rs10010131 with acute glucose-dependent insu-
lin secretion, we plotted C-peptide levels at 30 min of the
OGTT against glucose levels at the same time point. At this
time, variation of glucose is most pronounced and C-
peptide levels are hardly inﬂuenced by clearance. C-
peptide was adjusted for possible confounders (sex, age,
and BMI) by multivariate linear regression analysis. In
carriers of the nonrisk alleles of the TCF7L2 and WFS1
SNPs, the C-peptide rises with higher glucose concentra-
tions. By contrast, this relation is blunted in carriers of the
risk alleles (Fig. 2). Using insulin instead of C-peptide
yielded comparable results (supplementary Fig. 1).
TABLE 1
Interaction of glucose120, AUCGlucose, and A1C with SNPs on insulin secretion
Glucose120 AUCGlucose A1C
IGI
AUCC-peptide/
AUCGlucose IGI
AUCC-peptide/
AUCGlucose IGI
AUCC-peptide/
AUCGlucose
KCNJ11 rs5215 0.5 0.3 0.9 0.3 0.5 0.2
KCNQ1 rs151290 0.0498 0.3 0.4 0.4 0.8 0.5
SLC30A8 rs13266634 0.1 0.3 0.2 0.3 0.7 1.0
CDKAL1 rs7754840 0.6 0.1 0.4 0.05 0.6 0.3
CDKN2B rs10811661 0.7 0.08 0.6 0.3 0.6 0.3
IGF2BP2 rs4402960 0.5 0.4 0.2 0.5 0.4 0.6
MTNR1B rs10830963 1.0 0.7 0.3 0.9 0.6 0.5
TCF7L2 rs7903146 0.0017 0.0018 0.0006 0.0001 0.0438 0.0487
WFS1 rs10010131 0.0076 0.0002 0.0241 0.0003 0.05 0.0162
HHEX rs7923837 0.0055 0.2 0.0186 0.2 0.3 0.4
Data are P values determined using the additive inheritance model. Data in bold represent statistical signiﬁcance.
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impact of genetic variance in TCF7L2 on changes in
insulin secretion during a longitudinal lifestyle interven-
tion study. We found a signiﬁcant interaction between
TCF7L2 genotype and glycemia (glucose at 120 min of the
OGTT) at baseline on change in insulin secretion (P value
using the dominant inheritance model  0.0027) in a
model including sex, age, insulin secretion at baseline,
change in BMI, and change in glucose at 120 min of the
OGTT. Participants with IGT at baseline who carried the T
risk allele showed a signiﬁcant increase in insulin secre-
tion during lifestyle intervention compared with partici-
pants with NGT at baseline. No differences in change of
insulin secretion between subjects with NGT and IGT
were present in carriers of the wild-type C-allele (Fig. 3).
For WFS1 rs10010131, we found no signiﬁcant interaction
using the same model as described above (P  0.5).
DISCUSSION
In the present study, we demonstrated an interaction
between SNP effects on insulin secretion and glucose
levels for 2 of the 10 tested SNPs, i.e., in TCF7L2
rs7903146 and WFS1 rs10010131. Both SNPs were found to
impair incretin-stimulated insulin secretion (13,15). It is
well known that incretins are biologically effective only
under high glucose conditions (9). Therefore, it seems
plausible that the effects of these variants are more
pronounced when glucose levels are elevated. The genetic
variation in the other diabetes risk genes associated with
reduced insulin secretion (KCNJ11, SLC30A8, CDKAL1,
CDKN2A/2B, MTNR1B, HHEX, KCNQ1, and IGF2BP2)
did not show such an interaction. Therefore, their impact
is constantly present over the whole range of glucose
levels from NGT to IGT and overt diabetes.
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FIG. 1. Association between IGI and glucose 120 min by TCF7L2 SNP rs7903146 (A) and WFS1 SNP rs10010131 (B). Association between
AUCC-peptide/AUCGlucose and glucose120 by TCF7L2 SNP rs7903146 (C) and WFS1 SNP rs10010131 (D). Lines represent regression lines. Data were
loge-transformed prior to statistical analysis and adjusted for sex, age, BMI, and OGTT-derived insulin sensitivity index by multivariate linear
regression analysis.
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risk alleles when glucose levels reach values deﬁning IGT.
Thus, it may be important to lower glucose levels early in
subjects with these risk variants as a primary prevention in
subjects in the prediabetic and pre-IGT states.
To test this hypothesis, we analyzed the change in
insulin secretion during a lifestyle intervention with im-
proving glycemia in relation to baseline glycemia and
genetic variation in TCF7L2. We took advantage of the
Tu ¨bingen Lifestyle Intervention Program (TULIP), which
uses an intervention similar to those of the Finnish Diabe-
tes Prevention Study (DPS) and U.S. Diabetes Prevention
Program (DPP) (19,20). This intervention, based on di-
etary advice and increase of physical activity, improves
mainly insulin sensitivity (11). We previously reported that
the risk allele of TCF7L2 rs7903146 is associated with less
weight loss in response to this lifestyle intervention (21).
Improvement in insulin sensitivity and glucose levels was
not dependent on the genotype. Furthermore, insulin
secretion did not change during lifestyle intervention (21).
However, in our present analysis, we found that increased
glucose levels before lifestyle intervention predicted an
increase in insulin secretion in carriers of the risk alleles
of TCF7L2 rs7903146. This was not the case in carriers of
the nonrisk allele. Thus, speciﬁcally subjects with IGT on
the eve of diabetes who carry the TCF7L2 rs790314 risk
allele proﬁt from dietary and exercise interventions de-
signed to lower glucose levels by improving insulin sensi-
tivity. A plausible explanation may be that the relative
impairment of the incretin effect in carriers of the risk
allele is secondary to chronic hyperglycemia, and thus the
lifestyle intervention, by normalizing the hyperglycemia in
these subjects, would also restore the insulinotropic effect
of incretins.
These ﬁndings are consistent with the ﬁndings of the
DPS and DPP studies, in which the TCF7L2 genotype has
an effect on the progression from IGT to diabetes in the
control group but not in the lifestyle intervention group
(22,23). This indicates that lifestyle intervention can miti-
gate the risk conferred by genetic background. On the
basis of our data, we hypothesize that improving blood
glucose by improving insulin sensitivity as was achieved
by lifestyle intervention in the DPS, DPP, and TULIP
studies reduces the need for compensatory insulin hyper-
secretion. Therefore, the contribution of incretin action on
insulin secretion that is impaired in risk allele carriers
becomes less important.
The interaction of glycemia with genetic variation in
genes associated with insulin secretion also has further
implications for gentopye-phenotype association studies.
The interaction between genetic and environmental fac-
tors such as glucose control may hinder the detection of
other SNPs in cross-sectional studies (24). To avoid this,
knowledge of such environmental factors might be of
great value when analyzing case-control data, and addi-
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FIG. 2. Association between C-peptide levels at 30 min of the OGTT and glucose levels at 30 min during the OGTT by TCF7L2 SNP rs7903146 (A)
and WFS1 SNP rs10010131 (B). Lines represent regression lines. Data were loge-transformed prior to statistical analysis. C-peptide data are
adjusted for sex, age, and BMI by multivariate linear regression analysis.
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FIG. 3. Associations between fold-change in insulin secretion (mea-
sured by IGI) during 9-month lifestyle intervention and at baseline
glucose tolerance status. Participants with IGT at baseline who carried
the T risk allele showed a signiﬁcant increase in insulin secretion
compared with participants with NGT at baseline. No differences in
change of insulin secretion between subjects with NGT and IGT were
present in carriers of the wild-type C-allele. Padd, P values determined
using the additive inheritance model.
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performed.
A question raised by our data is whether SNPs with
stronger effects under high glucose conditions determine
the further progression toward the disease. One might
hypothesize that effects of the risk allele suppress insulin
secretion even stronger in the IGT state and therefore
might accelerate conversion toward type 2 diabetes. To
test this assumption further prospective studies are
needed.
Among the limitations of our study is the fact that we
could only detect relatively large effect sizes, and the study
was therefore underpowered to detect smaller effect sizes.
Indeed, because we tested 10 SNPs in parallel, only 2 of
them reached statistical signiﬁcance after Bonferroni cor-
rection. Thus, to verify our ﬁndings, additional studies in
larger cohorts including subjects with other ethnic back-
grounds are needed. For example, we did not detect an
interaction effect of WFS1 and glucose levels at baseline
on change in insulin secretion in the longitudinal lifestyle
intervention study. This might be due to the relative low
number of subjects that could be included in this analysis.
Furthermore, our cohort was also not balanced between
sexes and a single OGTT was used to measure glucose
levels for each participant, thus not taking into account
day-to-day variability. The fact that we observed interac-
tions with 120 min glucose but not with A1C may be due to
the relatively low power of the study or to glycemia-
independent factors that alter A1C levels.
Taken together, we found that glucose control deter-
mines the effects of certain SNPs on insulin secretion. The
effects of both TCF7L2 rs7903146 and WFS1 rs10010131
worsen with rising glucose levels, and both SNPs are
associated with impaired incretin action on insulin secre-
tion. This indicates the relevance of SNPs in different
stages of the pathogenesis toward type 2 diabetes (7,25) as
well as prevention strategies for type 2 diabetes.
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